GeoVax Receives Notice Of Allowance For HIV Vaccine Patent
Portfolio Pulse from Benzinga Newsdesk
GeoVax Labs, Inc. (NASDAQ:GOVX) has received a Notice of Allowance for Patent Application No. 17/409,574 titled 'Multivalent HIV Vaccine Boost Compositions and Methods of Use' from the U.S. Patent and Trademark Office. The patent covers a priming vaccination with a DNA vector encoding multiple HIV antigens in virus-like particles (VLPs), followed by a boost vaccination with GeoVax's vector platform for expressing HIV-1 antigens in VLPs utilizing an MVA viral vector. The company's HIV program forms an important part of the dataset underpinning all of its MVA-based development programs.
October 05, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GeoVax Labs has received a patent for its HIV vaccine, which forms an important part of the dataset underpinning all of its MVA-based development programs. This could potentially increase the company's value and attract more investors.
The patent for the HIV vaccine could potentially increase the company's value as it provides a competitive advantage and could attract more investors. This could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100